ClinicalTrials.gg
Not yet recruitingNCT07466303Updated Mar 12, 2026

Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer

A Phase 2 interventional study of Serplulimab and SHR-A1811 in Breast Cancer and Serplulimab Combined With SHR-A1811 as Neoadjuvant Therapy for Triple-Negative Breast Cancer, sponsored by Xijing Hospital. Not yet recruiting at 1 site in China. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-03-12.

Primary conditionTriple Negative Breast NeoplasmsRegistry: Breast NeoplasmsReclassifiedWhy we changed it
Registry
Breast Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Triple Negative Breast Neoplasms
Why
  1. The study's listed conditions name Triple Negative Breast Neoplasms, a narrower term within Breast Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Xijing Hospital · Phase 2, Interventional, and Treatment

How we know · 5 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
84
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 252 studies in Triple Negative Breast Neoplasms with a site in China — 126 open to participants now, 153 under way, 33 of them phase 3. Triple Negative Breast Neoplasms · China.

Planned enrollment
120th of 235
84 · median 90
Started
2026
with 31 others
Phase 2
124 of 252
65 open now
Primary completion
2028-02
later than 120 of 152 live
Registered
230th of 252
by date

Among the 252 studies in Triple Negative Breast Neoplasms with a site in China, this one is the 120th largest by planned enrollment of the 235 interventional ones that give a count, is one of 32 that started in 2026, is one of 124 in phase 2, reaches primary completion later than 120 of the 152 other live ones, and was the 230th registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 441 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

126 of the 252 studies in Triple Negative Breast Neoplasms with a site in China are open now. Recruiting first, the newest first:

121 more — sign in →

All 126 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 329 Triple Negative Breast Neoplasms studies recruiting now, 229 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 252 studies in Triple Negative Breast Neoplasms with a site in China, or all of them as a file.
02

Study summary

To evaluate the efficacy and safety of Serplulimab in combination with Trastuzumab Restuzumab for the neoadjuvant treatment of triple-negative breast cancer, aiming to provide evidence for optimizing the strategy of combining immunotherapy with ADC drugs in the neoadjuvant setting.

Read the detailed description

This is a prospective, single-arm, open-label, Phase II clinical trial investigating the efficacy and safety of a non-chemotherapy regimen comprising Serplulimab (an anti-PD-1 monoclonal antibody) and Trastuzumab Restuzumab (SHR-A1811, an antibody-drug conjugate) as neoadjuvant therapy for early-stage triple-negative breast cancer.

Primary Objective:To assess the pathological complete response rate, defined as the absence of invasive carcinoma in both the breast and sampled regional lymph nodes (ypT0/Tis ypN0), following neoadjuvant treatment with serplulimab plus SHR-A1811.

Secondary Objectives:

To evaluate invasive disease-free survival, event-free survival, and the objective response rate according to RECIST 1.1 criteria.

To determine the rate of breast-conserving surgery. To characterize the safety and tolerability profile of the combination regimen, including the incidence and severity of adverse events.

Study Design:

This study employs a Simon's two-stage, single-arm design. Approximately 84 treatment-naïve female patients with early-stage TNBC (clinical stage T1cN1-2 or T2-4N0-2) will be enrolled. Participants will receive six cycles of serplulimab and SHR-A1811 prior to definitive surgery. The primary endpoint will be centrally assessed on the surgical pathology specimen.

Interventions:

Serplulimab: Administered intravenously at a protocol-specified dose every three weeks for six cycles.

SHR-A1811: Administered intravenously at a protocol-specified dose every three weeks for six cycles.

Statistical Methods:

The study is designed to test the hypothesis that the combination regimen will increase the pCR rate from a historical benchmark of 30% to 40%. With a one-sided alpha level of 0.05 and 80% statistical power, a minimum of 75 evaluable patients is required. Allowing for an estimated 10% dropout rate, a total of 84 patients will be enrolled. The primary efficacy analysis of the pCR rate will be conducted on the full analysis set using an exact binomial test. The 95% confidence interval for the pCR rate will be calculated via the Clopper-Pearson exact method. Time-to-event endpoints will be analyzed using the Kaplan-Meier method.

03

Conditions studied

  • Breast Cancer
  • Serplulimab Combined With SHR-A1811 as Neoadjuvant Therapy for Triple-Negative Breast Cancer

Browse trials for

Keywords

  • Neoadjuvant Therapy
  • Pathological Complete Response
  • Serplulimab
  • PD-1 Inhibitor
  • Antibody-Drug Conjugate
  • Trastuzumab Deruxtecan
  • Phase II Clinical Trial
  • Triple-Negative Breast Cancer
  • HER2-Low Breast Cancer
04

In context

Triple Negative Breast Neoplasms Reclassified

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 441 are open to participants now.

This study's planned enrollment of 84 is above the median of 60 across 1,053 interventional studies indexed under Triple Negative Breast Neoplasms.

Browse Triple Negative Breast Neoplasms studies →

Lead sponsor

Xijing Hospital is the lead sponsor of 475 studies on the registry; 158 are open to participants now.

Compared within Triple Negative Breast Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Breast Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female patients aged 18 to 70 years, inclusive.
  • confirmed, treatment-naïve, early-stage triple-negative breast cancer (TNBC), defined as estrogen receptor (ER) and progesterone receptor (PR) expression \<1% by immunohistochemistry (IHC), and human epidermal growth factor receptor 2 ()-negative (IHC 0/1+ or IHC 2+ with negative in situ hybridization confirmation) per current American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines.
  • Clinical stage T1cN1-2 or T2-4N0-2 according to the American Joint Committee on Cancer (AJCC) staging system, 8th edition.
  • At least one as defined by (RECIST) version 1.1.
  • (ECOG) performance status of 0 or 1.
  • Adequate hematologic, hepatic, renal, and cardiac function within 14 days prior to enrollment:

    • Hematologic: (ANC) ≥1.5 × 10⁹/L; count ≥100 × 10⁹/L; ≥90 g/L (without transfusion or growth factor support within 14 days).
    • Hepatic: Total ≤1.5 × (ULN); (ALT) and aspartate aminotransferase (AST) ≤2.5 × ULN.
    • Renal: Serum creatinine and blood urea nitrogen (BUN) ≤1.5 × ULN.
    • Cardiac: (LVEF) ≥50% measured by echocardiogram; interval (QTc) \<470 ms on 12-lead (ECG).
  • Willingness to provide archival or fresh tumor tissue sample for programmed death-ligand 1 () biomarker analysis using the 22C3 pharmDx assay.
  • Ability to understand and willingness to sign a written document.

Exclusion criteria

Exclusion Criteria:

  • Evidence of (Stage IV) disease or bilateral breast cancer at diagnosis.
  • Prior systemic anticancer therapy (including chemotherapy, endocrine therapy, immunotherapy, or biological therapy) for any within 4 weeks before the first dose of study treatment.
  • Diagnosis of any other malignancy within the past 5 years, except for adequately treated non-melanoma skin cancer, basal cell carcinoma, or carcinoma in situ of the cervix.
  • Known active infection with (HIV), virus (HBV-DNA ≥500 IU/mL), or virus (detectable HCV-RNA).
  • Active disease requiring systemic therapy within the past 2 years.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection requiring systemic antibiotic therapy within 2 weeks, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness that would limit compliance with study requirements.
  • History of allogeneic hematopoietic stem cell or solid organ transplantation.
  • Pregnant or lactating women, or women of who are unwilling to use a highly effective method of during the treatment period and for at least 7 months after the last dose.
  • Known to any component of serplulimab or SHR-A1811.
  • Any condition that, in the opinion of the investigator, would compromise patient safety or interfere with the completion of the study procedures.
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
84 participants (estimated)

Study arms

  • Experimental
    Neoadjuvant Serplulimab + SHR-A1811

    All enrolled participants will receive the investigational combination therapy as neoadjuvant treatment. This regimen consists of Serplulimab (an anti-PD-1 monoclonal antibody) and SHR-A1811 (Trastuzumab Restuzumab , an antibody-drug conjugate). Both agents are administered intravenously every 3 weeks (Q3W) for 6 cycles prior to definitive surgery. The primary objective is to evaluate the efficacy and safety of this chemotherapy-free combination in patients with early-stage triple-negative breast cancer (TNBC).

    Drug: Serplulimab · Drug: SHR-A1811

Interventions

  • Administered intravenously at a protocol-specified dose, once every 3 weeks (Q3W), for a total of 6 cycles in the neoadjuvant setting.

  • DrugTrastuzumab rezetecanStudies of Trastuzumab rezetecanTrastuzumab rezetecan pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Administered intravenously at a protocol-specified dose, once every 3 weeks (Q3W), for a total of 6 cycles in the neoadjuvant setting.

07

What researchers measure

Primary outcomes

  1. Pathological Complete Response (pCR) Rate

    Proportion of participants achieving a pathological complete response, defined as the absence of residual invasive cancer in the breast and sampled ipsilateral lymph nodes (ypT0/Tis, ypN0) upon pathological review of the surgical resection specimen following completion of neoadjuvant therapy.

    Time frame: At the time of definitive surgery (after 6 cycles of neoadjuvant therapy; each cycle is 21 days).

Secondary outcomes

  1. Objective Response Rate (ORR)

    Proportion of participants achieving a best overall response of complete response or partial response, as assessed by the investigator per Response Evaluation Criteria in Solid Tumors version 1.1 during the neoadjuvant treatment phase.

    Time frame: From baseline until the end of neoadjuvant therapy (up to 6 cycles), with tumor assessments performed at the end of Cycles 2, 4, and 6(each cycle is 21days).

  2. Invasive Disease-Free Survival (iDFS)

    Time from the date of definitive surgery to the date of the first occurrence of invasive ipsilateral breast tumor recurrence, invasive loco-regional recurrence, distant recurrence, or death from any cause.

    Time frame: From surgery until first documented iDFS event or death, assessed up to 5 years (60 months).

  3. Event-Free Survival (EFS)

    Time from the date of enrollment to the date of the first occurrence of any of the following: disease progression that precludes planned surgery, invasive local/regional or distant recurrence following surgery, or death from any cause.

    Time frame: From enrollment until first documented EFS event or death, assessed up to 5 years (60 months).

  4. Breast-Conserving Surgery Rate

    Proportion of participants who undergo successful breast-conserving surgery as the definitive surgical procedure following neoadjuvant therapy.

    Time frame: During surgery

  5. Incidence and Severity of Adverse Events

    Frequency, severity (graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0), and investigator-assessed relationship to study treatment of all adverse events and serious adverse events.

    Time frame: From first study treatment administration until 30 days after the last dose (approximately 25 weeks).

08

Study locations

1 site
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2026; primary completion for Feb 2028, 22 months later.

Of 220 non-industry phase 2 interventional studies under Triple Negative Breast Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 99. This study's planned 22 months is below that.

Counting every sponsor, half of 255 studies reached it within 59 months; a quarter within 37 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2026
First posted
Mar 12, 2026
StartEst.
Mar 25, 2026
Primary completionEst.
Feb 1, 2028
CompletionEst.
Apr 1, 2031
Last update
Mar 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07466303
Lead sponsor
Xijing Hospital
Responsible party
Sponsor
First posted
Mar 12, 2026
Start date
Mar 25, 2026 (estimated)
Primary completion
Feb 1, 2028 (estimated)
Completion
Apr 1, 2031 (estimated)
Last update
Mar 12, 2026

Study contacts

Ju Liang Zhang, Prof
Contact
vascularzhang@163.com
029-84775271
Mei Ling Huang, MD
Contact
huangmeiling@126.com
029-84775271

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion